ArticlePloS one2013
5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Regulation of translation by upstream translation initiation codons of surfactant protein A1 splice variants.American journal of physiology. Lung cellular and molecular physiology · 2015Trial
- Case Report: A heterozygous loss-of-function variant of theFrontiers in cardiovascular medicine · 2025Article
- Identification and characterization of novel ETV4 splice variants in prostate cancer.Scientific reports · 2023Article
- The immune mechanism of the nasal epithelium in COVID-19-related olfactory dysfunction.Frontiers in immunology · 2023Review
- Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer.Cell & bioscience · 2022Article
- Article
- Impact TMPRSS2-ERG Molecular Subtype on Prostate Cancer Recurrence.Life (Basel, Switzerland) · 2021Article
- Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.Molecular & cellular proteomics : MCP · 2021Article
- The Untranslated Regions of mRNAs in Cancer.Trends in cancer · 2019Review
- The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.Translational oncology · 2019Article
- Optical coding of fusion genes using multicolor quantum dots for prostate cancer diagnosis.International journal of nanomedicine · 2017Article
- Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG.Vascular pharmacology · 2016Review
- Sequence-function correlations and dynamics of ERG isoforms. ERG8 is the black sheep of the family.Biochimica et biophysica acta · 2016Article
- The oncogene ERG: a key factor in prostate cancer.Oncogene · 2016Review
- Expression of ERG protein in prostate cancer: variability and biological correlates.Endocrine-related cancer · 2015Article
- Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.Journal of translational medicine · 2015Article
- Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.The American journal of pathology · 2014Article
- Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.Genes & cancer · 2014Article
- Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Alternative splicing programs in prostate cancer.International journal of cell biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ERG, a member of the ETS transcription factor family, is frequently overexpressed in prostate cancer as a result of its fusion to the androgen-responsive Tmprss2 gene. Different genomic rearrangements and alternative splicing events around the junction region lead to multiple combination of Tmprss2:ERG fusion transcripts that correlate with different tumor aggressiveness, but their specific functions and biological activities are still unclear. The complexity of ERG expression pattern is compounded by the use of alternative promoters, splice sites, polyadenylation sites and translation initiation sites in both the native and fusion contexts. Our systematic characterization of native ERG and Tmprss2:ERG variants reveals that their different oncogenic potential is impacted by the status of the Ets domain and the configuration of the 5' UTR region. In particular, expression and activity of functional ERG and Tmprss2:ERG variants are influenced both by translation initiation signals within the different isoforms and by inhibitory upstream Open Reading Frames (uORF) in their 5' UTRs. Stable expression of ERG and Tmprss2:ERG variants promoted cell migration/invasion, induced a block of proliferation and induced a senescence-like state, suggesting a role for these variants in the prostate tumorigenesis process. In addition to Tmprss2:ERG fusion products, a group of related native ERG isoforms is also highly over-expressed in fusion-carrying prostate cancers, and share the same translation initiation site (in ERG exon 4) with the commonly observed Tmprss2 exon1 joined to ERG exon 4 (T1:E4) fusion-derived variant. Usage of this ATG can be preferentially down-regulated by directed antisense-based compounds, possibly representing the basis of a targeted approach that distinguishes between tumor-associated and normal ERG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.